Introduction
The mammalian target of rapamycin (mTOR), a serine/ threonine kinase, lies downstream of phosphatidylinositol 3 0 -kinase, and is a central controller of cell proliferation and growth (Wullschleger et al., 2006) . Two mTOR complexes (TORC1 and TORC2) have recently been identified (Guertin and Sabatini, 2007) . TORC1 consists of mTOR, mLST8 (also termed G-protein b-subunit-like protein, GbL, a yeast homolog of LST8), PRAS40 (proline-rich Akt substrate 40 kDa) and raptor (regulatory-associated protein of mTOR), and is sensitive to rapamycin (Hara et al., 2002; Kim et al., 2002 Kim et al., , 2003 Loewith et al., 2002; Fonseca et al., 2007; Sancak et al., 2007; Vander Haar et al., 2007) . TORC2 is composed of mTOR, mLST8, mSin1 (mammalian stress-activated protein kinase-interacting protein 1), rictor (rapamycin-insensitive companion of mTOR) and protor (protein observed with rictor), and is insensitive to rapamycin (Jacinto et al., 2004 (Jacinto et al., , 2006 Sarbassov et al., 2004; Frias et al., 2006; Yang et al., 2006; Pearce et al., 2007) . TORC1 regulates phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) (Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002) , and TORC2 phosphorylates Akt at S473 (Sarbassov et al., 2005) . Although the cellular functions of the mTOR complexes remain to be determined, current data indicate that the phosphatidylinositol 3 0 -kinase-mTOR signaling pathway regulates many cellular events, such as cell proliferation and growth, differentiation, survival and motility (Wullschleger et al., 2006; Guertin and Sabatini, 2007) .
A variety of transformed or tumor cells with dysregulated mTOR signaling have shown higher susceptibility to inhibitors of mTOR than normal cells, forming a rationale for mTOR inhibitors as potential tumor-selective therapeutic agents. Clinical trials have demonstrated that rapamycin analogs CCI-779, RAD001 and AP23573 (designated rapamycins) are promising anticancer drugs. They specifically block the function of mTOR, inhibiting growth of numerous solid tumors (renal, breast, prostate, colon and brain cancers) with only mild side effects. Recently, the U.S. Food and Drug Administration approved Torisel, Wyeth) for the treatment of advanced renal cell carcinoma, further revealing the potentiality of rapamycins in cancer therapy. However, to date, the anticancer mechanism of rapamycins remains to be defined. While intensive studies have focused on the antiproliferative activity of rapamycins, their inhibitory effect on cell motility is only beginning to be recognized. Recently, inhibition of motility and invasion by rapamycin has been described in numerous cell lines in culture . In vivo, rapamycin also potently inhibits metastases of transplanted tumors derived from murine adenocarcinoma cells (CT-26) (Guba et al., 2002) , human renal cancer cells (RCC 786-O) (Luan et al., 2003) , murine non-small cell lung cancer cells (Boffa et al., 2004) and osteosarcoma (K7M2) (Wan et al., 2005) in mice. The data indicate that rapamycin is a potent inhibitor not only for cell proliferation and growth, but also for cell motility.
The type I insulin-like growth factor (IGF-I) receptor and its ligands, IGF-I and IGF-II, play critical roles in the regulation of cellular proliferation, survival and transformation (Wullschleger et al., 2006; Guertin and Sabatini, 2007) . Increasing evidence indicates that IGF-I signaling is also pivotal to cell motility and invasion (LeRoith and Roberts, 2003) . IGF-I-induced cell motility has been characterized in various cell types (Kadowaki et al., 1986; Leventhal et al., 1997; Guvakova and Surmacz, 1999) . The earliest detectable morphological change induced by IGF-I is the reorganization of the actin cytoskeleton associated with the formation of lamellipodia (Kadowaki et al., 1986; Leventhal et al., 1997; Guvakova and Surmacz, 1999) . Activation of the phosphatidylinositol 3 0 -kinase pathway by IGF-I is essential for this process, which is regulated through focal adhesion proteins, such as focal adhesion kinase (FAK), paxillin and p130
Cas (Kadowaki et al., 1986; Leventhal et al., 1997; Guvakova and Surmacz, 1999) . IGF-I induces rapid tyrosine phosphorylation of FAK, paxillin and p130
Cas in human neuroblastoma cells (SH-SY5Y) and Swiss 3T3 cells (Leventhal et al., 1997; Guvakova and Surmacz, 1999) , although disputation exists (Konstantopoulos and Clark, 1996; Casamassima and Rozengurt, 1998) . However, whether and how mTOR is involved in the regulation of F-actin reorganization is poorly understood, which links to the mechanism by which rapamycin inhibits cell motility. To address this issue, we studied whether rapamycin inhibition of cell motility is related to its prevention of F-actin reorganization. Here, we show that rapamycin inhibits IGF-I-induced F-actin reorganization in a panel of tumor cell lines, such as human rhabdomyosarcoma (Rh30) and Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells. This may be related to rapamycin inhibition of IGF-I-induced phosphorylation of focal adhesion proteins (FAK, paxillin and p130 Cas ) , which is dependent on mTOR kinase activity. Disruption of mTORraptor complex, mimicking the effect of rapamycin, prevented IGF-I-stimulated F-actin reorganization and phosphorylation of the focal adhesion proteins. Both S6K1 and 4E-BP1 pathways are involved in the regulation of F-actin reorganization, but only the former controls phosphorylation of the focal adhesion proteins.
Results
Rapamycin inhibits IGF-I-stimulated F-actin reorganization in an mTOR kinase activity-dependent manner Cell migration is a highly concerted, cyclical and multistep process, including cell polarization/protrusion, adhesion and de-adhesion (Ridley et al., 2003) . Inhibition of any of these steps may impair cell motility. Recently, we have demonstrated that rapamycin inhibits IGF-I-stimulated cell motility . To further understand the underlying mechanism, this study first examined whether rapamycin inhibition of cell motility is related to its prevention of cell polarization/protrusion (F-actin reorganization). Consistent with a previous report , we found that rapamycin inhibited basal and IGF-I-stimulated motility of rhabdomyosarcoma (Rh30), glioblastoma (U-373), prostate cancer (PC-3) and Ewing sarcoma (Rh1) cells (Figure 1a ). Of interest, in response to stimulation with IGF-I (10 ng/ml), the actin cytoskeleton in Rh30 cells (upper panel, Figure 1b ) underwent rapid reorganization. In the absence of IGF-I, F-actin was randomly distributed across Rh30 cells, as revealed by staining with FITC-conjugated phalloidin. Some F-actin was condensed in dot-like structures at the margins of the cells. However, within 1 h of stimulation with IGF-I, more F-actin was condensed at the leading edge within structures resembling fans or protrusions (termed lamellipodia, see arrows), compared to non-treated control cells. Rapamycin did not obviously alter the pattern of basal F-actin distribution. In contrast, treatment with rapamycin (100 ng/ml) for 2 h dramatically reduced IGF-I-stimulated F-actin reorganization at the leading edge. To examine whether this is dependent on cell type, we also examined the effect of rapamycin on IGF-I-stimulated lamellipodia formation in other three highly motile cell lines, including U-373, PC-3 and Rh1 cells. Similar results were observed in U-373, PC-3 ( Figure 1b ) and Rh1 cells (data not shown). The data suggest that rapamycin inhibition of cell motility is correlated to its prevention of F-actin reorganization.
To determine the role of mTOR kinase activity in IGF-I-stimulated lamellipodia formation, Rh1 and Rh30 clones expressing empty vector (pcDNA), rapamycin-resistant mutant mTOR (mTORrr) and kinase dead (mTOR-SIDA) were pretreated with or without rapamycin for 2 h, followed by stimulation with or without IGF-I for 1 h. We found that rapamycin failed to inhibit IGF-I-induced F-actin reorganization in Rh30 cells stably expressing mTORrr (middle panel, Figure 2a ). In contrast, cells stably expressing an empty vector (pcDNA3) (upper panel, Figure 2a ) or a kinasedead mTORrr (mTOR-SIDA) remained sensitive to rapamycin (bottom panel, Figure 2a ). Similar data were observed in Rh1 cells (data not shown). The results suggest that IGF-I-induced F-actin reorganization is regulated in an mTOR kinase activity-dependent manner.
We also confirmed the above finding using RNA interference. As shown in Figure 2b , lentiviral short hairpin RNA (shRNA) to mTOR silenced expression of mTOR protein by B90% in Rh30 cells, comparing with the control shRNA (to green fluorescence protein (GFP)). Downregulation of mTOR, mimicking the effect of rapamycin, dramatically decreased the mTOR kinase activity, since the basal or IGF-I-stimulated phosphorylation of S6K1 at T389, routinely used as an indicator of mTOR kinase activity (Wullschleger et al., 2006; Guertin and Sabatini, 2007) , was not detectable by western blot (Figure 2b ). As expected, downregulation of mTOR obviously prevented IGF-I-stimulated F-actin reorganization (Figure 2c ). mTOR-raptor complex controls F-actin reorganization Two mTOR complexes (TORC1, mTOR-raptor, and TORC2, mTOR-rictor) have been identified recently (Guertin and Sabatini, 2007) . Disruption of TORC2 prevents cell spreading and F-actin polymerization of NIH 3T3 cells (Jacinto et al., 2004) , and inhibits cell motility . However, TORC2 is rapamycin insensitive (Jacinto et al., 2004; Sarbassov et al., 2004) . As described above, we have found that rapamycin inhibits F-actin reorganization in an mTORdependent manner. Therefore, we reasoned involvement of TORC1 in the regulation of such cellular event as well. To this end, lentiviral shRNA to raptor was used to downregulate raptor in Rh30 cells. Lentiviral shRNA to rictor was set as a positive control. shRNAs to raptor and rictor, but not the control shRNA to GFP, downregulated the protein levels of raptor and rictor by 90 and 85%, respectively (versus control) in the cells (Figure 3a) . Consistent with previous findings (Hara et al., 2002; Kim et al., 2002; Jacinto et al., 2004; Sarbassov et al., 2004 Sarbassov et al., , 2005 , downregulation of raptor, but not rictor, blocked mTOR-mediated phosphorylation of S6K1 and 4E-BP1, mimicking the effect of rapamycin, whereas downregulation of rictor inhibited phosphorylation of Akt ( Figure 3a) . Of interest, downregulation of rictor dismantled F-actin stress fibers, Figure 3b ). The above data suggest that both TORC1 and TORC2 are involved in the regulation of F-actin reorganization, but only disruption of TORC1 mimicked the effect of rapamycin treatment. Also, the two mTOR complexes may regulate F-actin reorganization through different mechanisms.
Both S6K1 and 4E-BP1 pathways are essential for the regulation of F-actin reorganization Phosphorylation of S6K1 has been reported to colocalize with F-actin arc at the leading edge in NIH 3T3 cells (Berven et al., 2004) . However, whether rapamycin inhibits F-actin reorganization through TORC1-mediated S6K1 and/or 4E-BP1 pathways is not clear. To address this question, expression of constitutively active and rapamycin-resistant S6K1 (S6K1-ca) and constitutively hypophosphorylated 4E-BP1 (4E-BP1-5A) was performed by infection of Rh30 cells with Ad-S6K1-ca and Ad-4EBP1-5A, respectively ( Figure 4a ). Expression of S6K1-ca, but not GFP alone, induced F-actin reorganization even without stimulation with IGF-I, and conferred to resistance to rapamycin inhibition of formation of lamellipodia ( Figure 4b ). In contrast, expression of 4E-BP1-5A, which binds eIF4E and quenches the function of eIF4E , inhibited lamellipodia formation in the presence of IGF-I ( Figure 4b ). We also confirmed the above findings using RNA interference technology. As shown in Figure 5a , Figure 2 Rapamycin prevents insulin-like growth factor 1 (IGF-I)-induced actin filaments (F-actin) reorganization in a mammalian target of rapamycin (mTOR) kinase activity-dependent manner. (a) Serum-starved (for 24 h) Rh30/pcDNA, Rh30/mTORrr and Rh30/ mTOR-SIDA cells grown on glass coverslips in 6-well plates were pretreated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml) for 1 h. F-actin was stained, as described in lentiviral shRNAs to 4E-BP1 and S6K1 downregulated protein expression of 4E-BP1 and S6K1 by B90%, respectively. When S6K1 was downregulated by lentiviral shRNA to S6K1, Rh30 cells failed to form lamellipodia in the presence of IGF-I (Figure 5b ). On the other hand, when 4E-BP1 was downregulated by lentiviral shRNA to 4E-BP1, formation of lamellipodia occurred at the leading edge of the cells even Expression of rapamycin-resistant and constitutively active S6K1 (S6K1-ca) induces lamellipodia formation and confers to resistance to rapamycin inhibition of actin filaments (F-actin) reorganization, whereas expression of constitutively hypophosphorylated 4E-BP1 (4E-BP1-5A) directly prevented insulin-like growth factor 1 (IGF-I)-stimulated F-actin reorganization. (a) Serumstarved Rh30 cells, infected with Ad-S6K1-ca, Ad-4EBP1-5A or Ad-GFP (control), were pretreated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml) for 1 h. Expression of HA-tagged S6K1-ca and 4E-BP1-5A were detected by western blotting with antibodies to HA. The function of rapamycin-resistant and constitutively active S6K1 (S6K1-ca) was confirmed by detecting the phosphorylation of ribosomal protein S6, the substrate of S6K1. b-tubulin was used for loading control. (b) F-actin was stained in Ad-S6K1-ca, Ad-4EBP1-5A or Ad-GFP infected Rh30 cells, respectively, as described in Figure 1 . Formation of lamellipodia is shown (arrows). Bar ¼ 20 mm.
Inhibition of mTOR suppresses phosphorylation of the focal adhesion proteins A close relationship between F-actin reorganization and tyrosine phosphorylation of focal adhesion proteins has been described (Leventhal et al., 1997; Guvakova and Surmacz, 1999; Leopoldt et al., 2001) . As IGF-I stimulation very quickly induced F-actin reorganization, next we examined whether IGF-I impacts tyrosine phosphorylation of the focal adhesion proteins in Rh1 and Rh30 cells. As shown in Figure 6 , stimulation with IGF-I (10 ng/ml) within 1 h did not alter the protein levels of FAK, paxillin and p130 Cas (Figure 6a ), but rapidly increased tyrosine phosphorylation of FAK, paxillin and p130
Cas in Rh1 cells (Figure 6b ). Robust tyrosine phosphorylation of FAK and paxillin was detectable within 5-10 min, and that of p130
Cas within 30-60 min. Similar data were observed in Rh30 cells (data not shown). As rapamycin prevents IGF-Iinduced change of F-actin reorganization in Rh1 (not shown) and Rh30 cells (Figure 1) , we have further examined the effect of rapamycin on IGF-I-stimulated tyrosine phosphorylation of the focal adhesion proteins. As shown in Figure 6c , pretreatment of Rh1 cells with rapamycin for 2 h markedly inhibited IGF-I-stimulated tyrosine phosphorylation of FAK, p130 Cas and paxillin. Furthermore, we found that rapamycin failed to inhibit IGF-I-induced phosphorylation of the focal adhesion proteins in the cells stably expressing mTORrr (S2035I) (Figure 6d ). In contrast, cells stably expressing an empty vector (pcDNA3) (data not shown) or a kinase-dead mTORrr (mTOR-SIDA) remained sensitive to rapamycin (Figure 6d) . The results suggest that rapamycin Downregulation of raptor mimicks the effect of rapamycin, inhibiting phosphorylation of the focal adhesion proteins As TORC1 regulates F-actin reorganization, next we examined whether the TORC1 regulates phosphorylation of the focal adhesion proteins. Lentiviral shRNA to raptor were used to disrupt TORC1. As TORC2 has been reported to regulate phosphorylation of paxillin (Jacinto et al., 2004) , shRNA to rictor was used as a control. As shown in Figure 7a , downregulation of raptor, but not GFP (control), inhibited IGF-I-stimulated tyrosine phosphorylation of FAK and paxillin, mimicking the effect of rapamycin. As expected, downregulation of rictor inhibited phosphorylation of paxillin and FAK as well (Figure 7a ). Consistent with previous findings (Hara et al., 2002; Kim et al., 2002) , rapamycin treatment only disrupted TORC1 (Figure 7b) . Therefore, we conclude that both TORC1 and TORC2 control tyrosine phosphorylation of FAK and paxillin, and rapamycin inhibits IGF-I-stimulated phosphorylation of the focal adhesion proteins through targeting TORC1.
TORC1-mediated S6K1, but not 4E-BP1 pathway, regulates phosphorylation of the focal adhesion proteins As S6K1 and 4E-BP1 are the best characterized effectors of TORC1 (Guertin and Sabatini, 2007) , we further determined which of them is responsible for mTORcontrolled phosphorylation of FAK and paxillin. First, the S6K1 pathway was studied. Rh30 cells were infected with recombinant adenoviruses expressing HA tagged constitutively active and rapamycin-resistant S6K1 mutant (F5A-E389-R3A) (Ad-S6K1-ca) and Ad-GFP (as controls). As shown in Figure 8a , overexpression of S6K1-ca, but not GFP, abrogated the inhibitory effect of rapamycin on tyrosine phosphorylation of FAK and paxillin. In contrast, downregulation of S6K1 by lentiviral shRNA mimicked rapamycin treatment, decreasing the IGF-I-stimulated tyrosine phosphorylation of FAK and paxillin (Figure 8b ). The results indicate that S6K1 is involved in the regulation of phosphorylation of the focal adhesion proteins. Next, 4E-BP1 pathway was investigated. As 4E-BP1 pathway affects F-actin reorganization, we expected that downregulation of 4E-BP1 would result in resistance to rapamycin inhibition of phosphorylation of FAK and paxillin. However, to our surprise, downregulation of 4E-BP1 by RNA interference failed to affect IGF-I-stimulated phosphorylation of FAK and paxillin in Rh30 cells (Figure 9a) , regardless of pretreatment with or without rapamycin. Similar data were observed in Rh1 cells (data not shown). Furthermore, ectopic expression of 4E-BP1-5A by infection of the cells with Ad-4EBP1-5A did not obviously alter the cellular protein levels of FAK and paxillin (Figure 9b) , and IGF-I-stimulated phosphorylation of the focal adhesion proteins (Figure 9c ). The data imply that TORC1-mediated 4E-BP1 pathway does not participate in the regulation of tyrosine phosphorylation of the focal adhesion proteins.
Discussion
Recently, we have shown that rapamycin inhibits cell motility . As cell migration is a multistep cellular event, including cell polarization/ protrusion, adhesion and de-adhesion (Ridley et al., 2003) , disturbance of any of these steps may affect cell motility. To further understand the underlying Figure 6 Rapamycin inhibits insulin-like growth factor 1 (IGF-I)-stimulated tyrosine phosphorylation of focal adhesion kinase (FAK), paxillin and p130
Cas . (a) and (b) Serum-starved Rh1 cells were stimulated with IGF-I (10 ng/ml) for the indicated time. An equivalent amount of protein (lysates) was used for western blot with antibodies to paxillin, FAK, p130
Cas and b-tubulin (loading control) (a). Immunoprecipitation was performed by incubation of cell lysates (500 mg) with mouse monoclonal antibody to phosphotyrosine (p-Tyr) (5 mg), plus protein A/G-agarose beads overnight at 4 1C, followed by immunoblotting with antibodies to FAK, paxillin or p130 Cas . Immunoglobulin G (IgG)-heavy chain (IgG-HC) and light chain (IgG-LC) from each immunoprecipitated sample are shown as loading control (b). (c) Serum-starved Rh1 cells or (d) Rh30/mTORrr and Rh30/mTOR-SIDA cells were pretreated with or without rapamycin (100 ng/ml) for 2 h, and then stimulated with IGF-I (10 ng/ml) for 10 min (for FAK and paxillin) or 1 h (for p130 Cas ). Immunoprecipitation was performed by incubation of cell lysates (500 mg) with antibodies to FAK, paxillin or p130
Cas , followed by immunoblotting with antibodies to p-Tyr, FAK, p130
Cas and paxillin, respectively.
Rapamycin inhibition of F-actin reorganization L Liu et al mechanism, this study was set to examine whether rapamycin inhibition of cell motility is related to its prevention of F-actin reorganization. Here, we show that rapamycin inhibits IGF-I-stimulated F-actin reorganization in a panel of tumor cell lines, such as human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, revealing that rapamycin may inhibit cell motility, at least by impairing cell polarization/protrusion. Furthermore, our data indicate that rapamycin may inhibit F-actin reorganization by suppression of mTOR-mediated phosphorylation of focal adhesion proteins, including FAK, paxillin and p130 Cas . It is well known that rapamycin inhibits proliferation and growth (Wullschleger et al., 2006; Guertin and Sabatini, 2007) or induces apoptosis of tumor cells under certain conditions (Hosoi et al., 1999; Huang et al., 2003) by inhibiting the kinase activity of mTOR. However, studies have also shown that rapamycin inhibits differentiation of C2C12 cells (Erbay and Chen, 2001) , which is independent of the kinase activity of mTOR, although this remains controversial (Erbay and Chen, 2001; Shu et al., 2002) . This prompted us to study whether rapamycin inhibits F-actin reorganization and phosphorylation of the focal adhesion proteins in an mTOR-kinase activity-dependent manner. We found that rapamycin failed to inhibit IGF-I-induced F-actin reorganization and phosphorylation of the focal adhesion proteins in the mTORrr-transfected cells, but not in control cells (empty-vector or mTOR-SIDA-transfected Figure 7 Rapamycin-sensitive mammalian target of rapamycin (mTOR)-raptor complex regulates phosphorylation of focal adhesion kinase (FAK) and paxillin. (a) Downregulation of raptor or rictor inhibited phosphorylation of FAK and paxillin. Serum-starved Rh30 cells that were infected with lentiviral small hairpin RNAs (shRNAs) to green fluorescence protein (GFP), raptor and rictor, respectively, were pretreated with or without Rapa (100 ng/ml) for 2 h, and then stimulated with insulin-like growth factor 1 (IGF-I) (10 ng/ml) for 10 min, followed by immunoprecipitation with mouse monoclonal antibody to p-Tyr antibody, and immunoblotting with antibodies to FAK and paxillin, respectively. Immunoglobulin G (IgG)-heave chain (IgG-HC) and light chain (IgG-LC) were served as loading control. (b) Rapamycin disrupts mTOR-raptor complex, but not mTOR-rictor complex. Serum-starved Rh30 cells were pretreated with Rapa (100 ng/ml) for 2 h, and then stimulated with IGF-I (10 ng/ml) for 1 h, followed by immunoprecipitation with anti-mTOR antibody, and immunoblotting with antibodies to raptor, rictor, mLST8 and mTOR, respectively. and Ad-S6K1-ca, respectively (a) or with lentiviral small hairpin RNAs (shRNAs) to GFP and S6K1, respectively (b), were pretreated with or without Rapa (100 ng/ml) for 2 h, and then stimulated with IGF-I (10 ng/ml) for 10 min, followed by immunoprecipitation with mouse monoclonal antibody to phosphotyrosine (p-Tyr) antibody, and immunoblotting with antibodies to FAK and paxillin, respectively.
Rapamycin inhibition of F-actin reorganization
L Liu et al cells), suggesting that the kinase activity of mTOR is essential for IGF-I-stimulated F-actin reorganization and phosphorylation of the focal adhesion proteins. Previous studies have demonstrated that disruption of TORC2 prevents cell spreading, F-actin polymerization and phosphorylation of paxillin in NIH 3T3 cells (Jacinto et al., 2004) . TORC2 is rapamycin insensitive (Wullschleger et al., 2006; Guertin and Sabatini, 2007) . As rapamycin inhibited IGF-I-induced lamellipodia formation and phosphorylation of the focal adhesion proteins, we therefore hypothesized that the rapamycinsensitive complex, TORC1, regulates F-actin reorganization and phosphorylation of the focal adhesion proteins as well. Our RNA interference data support this notion. Of interesting, looking through the data (Figure 2) , we found that TORC1 and TORC2 regulate F-actin reorganization in different ways, although both of them controls phosphorylation of the focal adhesion proteins. Downregulation of raptor, mimicking the effect of rapamycin, inhibited IGF-I-stimulated phosphorylation of S6K1 and 4E-BP1 and lamellipodia formation, but did not impact F-actin stress fibers. However, downregulation of rictor not only inhibited IGF-I-stimulated lamellipodia formation, but also dismantled F-actin stress fibers.
We also noticed that inhibition of mTOR by rapamycin or downregulation of raptor increased phosphorylation of Akt (Figure 2a) . This is consistent with recent findings (Tzatsos and Kandror, 2006) , and is probably the consequence of S6K1 inhibition. It has been reported that S6K1 phosphorylates insulin receptor substrate 1, promoting its degradation (Tremblay and Marette, 2001 ). Inhibition of S6K1 activity prevents phosphorylation of insulin receptor substrate 1 (S636/ 639), resulting in accumulation of insulin receptor substrate 1 and activation of its downstream kinases, such as phosphatidylinositol 3 0 -kinase and Akt, by a feedback regulating mechanism (Tremblay and Marette, 2001; O'Reilly et al., 2006; Tzatsos and Kandror, 2006; Wan et al., 2007) . Increased phosphorylation of Akt by raptor shRNA in the absence of rapamycin did not induce formation of lamellipodia in Rh30 cells (Figure 2b ), implying that Akt may not be involved in the regulation of lamellipodia formation, or at least Akt activity itself is not enough for lamellipodia formation, if TORC1-mediated S6K1 and 4E-BP1 pathways are blocked.
Our studies indicate that rapamycin may inhibit IGF-I-induced F-actin reorganization by targeting TORC1-mediated S6K1 and 4E-BP1 pathways. However, only S6K1 pathway was found to be involved in the regulation of phosphorylation of the focal adhesion proteins (FAK and paxillin). This is supported by the following findings: (1) Cells infected with an Figure 9 4E-BP1 pathway does not control phosphorylation of focal adhesion kinase (FAK) and paxillin. (a) Downregulation of 4E-BP1 or (b) expression of constitutively hypophosphorylated 4E-BP1 (4E-BP1-5A) does not affect rapamycin inhibition of insulin-like growth factor 1 (IGF-I)-stimulated phosphorylation of FAK and paxillin. Serum-starved Rh30 cells, infected with lentiviral small hairpin RNAs (shRNAs) to green fluorescence protein (GFP) and 4E-BP1, respectively (a) or with Ad-GFP and Ad-4EBP1-5A, respectively (b, c), were pretreated with or without Rapa (100 ng/ml) for 2 h, and then stimulated with IGF-I (10 ng/ml) for 10 min, followed by immunoprecipitation with mouse monoclonal antibody to phosphotyrosine (p-Tyr) antibody, and immunoblotting with antibodies to FAK and paxillin, respectively (a, c) or western blot analysis of cell lysates using the indicated antibodies (b).
Rapamycin inhibition of F-actin reorganization L Liu et al adenovirus expressing constitutively active and mTORrr of S6K1 conferred to resistance to rapamycin inhibition of IGF-I-stimulated F-actin reorganization and phosphorylation of FAK and paxillin. (2) IGF-I failed to stimulate F-actin reorganization and phosphorylation of FAK and paxillin in the S6K1-downregulated cells. (3) Expression of constitutively hypophosphorylated 4E-BP1 (4E-BP1-5A) inhibited IGF-I-stimulated F-actin reorganization, but did not alter phosphorylation of FAK and paxillin. Our data are in contrast to previous findings that FAK regulates phosphorylation of S6K1 (Malik and Parsons, 1996; Gan et al., 2006) . This is probably related to different cell types or approaches used. Gan et al. (2006) used 293 T cells overexpressing FAK and S6K1. In fact, they found that overexpression of wild-type FAK did not significantly impact phosphorylation of S6K1 in 293 T cells (Gan et al., 2006) . Only overexpression of a kinase-dead FAK (Gan et al., 2006) in 293 T cells or a dominant-negative FAK (FRNK) (Malik and Parsons, 1996) in chick embryo cells reduced phosphorylation of S6K1. Whether FAK really regulates S6K1 is challenged by other findings (Govindarajan et al., 2000) as well, because overexpression of FRNK did not affect phosphorylation of S6K1 in rat aortic vascular smooth muscle cells. The findings from this study and others (Jacinto et al., 2004) indicate that mTOR may regulate phosphorylation of the focal adhesion proteins, including FAK, paxillin and p130 Cas . Clearly, more studies are needed to elucidate the relationship between FAK and mTOR/S6K1. For example, early findings suggested that Akt fuctions as an upstream kinase, phosphorylating mTOR (Ser2448) (Nave et al., 1999; Sekulic et al., 2000) . However, latest data have demonstrated that mTOR (TORC2) phosphorylates Akt (Ser473) (Sarbassov et al., 2005) .
It remains unclear how 4E-BP1 pathway regulates F-actin reorganization. 4E-BP1 primarily functions as a suppressor of eIF4E (Wullschleger et al., 2006; Guertin and Sabatini, 2007) . Hypophosphorylated 4E-BP1 tightly binds to eIF4E, and prevents association of eIF4E with eIF4G and formation of the eIF4F initiation complex, thereby inhibiting cap-dependent translation of mRNA (Mothe-Satney et al., 2000; Wullschleger et al., 2006; Guertin and Sabatini, 2007) . In our studies, expression of 4E-BP1-5A, which sequesters the eIF4E , did not alter the cellular protein levels or phosphorylation levels of FAK and paxillin. We have further studied whether 4E-BP1 pathway may affect synthesis of other proteins, such as small GTPases (RhoA, Cdc42 and RacI), atypical PKC and integrins, which are associated with F-actin reorganization. Our new data suggest that 4E-BP1 pathway at least plays an important role in controlling protein synthesis of small GTPases. This is evidenced by the findings that expression of constitutively hypophosphorylated 4E-BP1 (4E-BP1-5A), mimicking the effect of rapamycin, severely inhibits protein synthesis of RhoA, Rac1 and Cdc42 (our unpublished observations). More studies are on the way to understand how 4E-BP1 pathway controls F-actin reorganization and cell motility.
In conclusion, we have shown that rapamycin inhibits IGF-I-induced F-actin reorganization and phosphorylation of the focal adhesion proteins by blocking the kinase activity of mTOR. This is attributed to rapamycin disruption of mTOR-raptor complex. Furthermore, both S6K1 and 4E-BP1 pathways, mediated by the mTOR-raptor complex, are involved in the regulation of IGF-I-stimulated F-actin reorganization. However, only S6K1 pathway controls IGF-I-stimulated phosphorylation of the focal adhesion proteins.
Materials and methods

Cell lines and cultures
Cell lines from human rhabdomyosarcoma (Rh30) (Huang et al., 2003) and Ewing sarcoma (Rh1) (gifts from Dr Peter J Houghton, St Jude Children's Research Hospital, Memphis, TN, USA) were grown in antibiotic-free RPMI 1640 medium (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) at 37 1C and 5% CO 2 . Human prostate carcinoma (PC-3) and glioblastoma (U-373) cells (American Type Culture Collection, Manassas, VA, USA) were grown in antibiotic-free Dulbecco's modified eagle medium (Mediatech) supplemented with 10% fetal bovine serum at 37 1C and 5% CO 2 . Human embryonic kidney 293 (American Type Culture Collection) and 293TD cells (Invitrogen, Carlsbad, CA, USA) were grown in antibiotic-free Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated fetal bovine serum at 37 1C and 5% CO 2 . For experiments where cells were deprived of serum, cell monolayers were washed with phosphatebuffered saline, and incubated in the serum-free Dulbecco's modified Eagle medium (Mediatech). Rh1 and Rh30 clones expressing pcDNA3 (empty vector, Invitrogen), AU1-tagged mTORrr and mTOR-SIDA (Sekulic et al., 2000) were generated as described (Hosoi et al., 1999) . mTORrr represents the entire mTOR gene with the site mutation (S2035I) that has intact mTOR kinase activity, but prevents FKBP12-rapamycin complex binding and is rapamycin resistant (Hosoi et al., 1999) . mTOR-SIDA stands for a catalytically inactive (kinase dead) mTORrr mutant (D2038A) (Sekulic et al., 2000) . Clones were expanded in growth medium containing G418 (500 mg/ml). Individual clones were screened for expression of the mutant proteins by western blot analysis with anti-AU1 antibodies (Bethyl Laboratories, Montgomery, TX, USA). The functions of mTORrr and mTORSIDA in the cells were conformed as described previously .
Recombinant adenoviral constructs and infection of cells
Constitutively hypophosphorylated mutant 4E-BP1 (Thr36A, Thr45A, Ser64A, Thr69A and Ser82A) (4E-BP1-5A) (Mothe-Satney et al., 2000) and constitutively active and rapamycin-resistant S6K1 (pRK7/HA-S6K1-F5A-E389-R3A) (Schalm et al., 2005) were gifts from Dr John Lawrence (University of Virginia, Charlottesville, VA, USA) and Dr John Blenis, Harvard Medical School, Boston, MA, USA), respectively. The recombinant adenoviruses encoding HA-tagged 4E-BP1-5A (Ad-4EBP1-5A), HA-tagged constitutively active and rapamycin-resistant S6K1 (Ad-S6K1-ca), and the control virus encoding the GFP alone (Ad-GFP) were generated, titrated and used, as described .
Lentiviral shRNA cloning, production and infection
To generate lentiviral shRNAs to 4E-BP1 and S6K1, oligonucleotides containing the target sequences were synthesized, annealed and inserted into FSIPPW lentiviral vector (Kanellopoulou et al., 2005) through the EcoR1/BamH1 restriction enzyme site. The following oligonucleiotides were used: 4E-BP1 sense: 5 0 -AATTCCCATTCCTGATGGAGTG TCGGTGCAAGAGACCGACACTCCATCAGGAATTTTT TG-3 0 , anti-sense: 5 0 -GATCCAAAAAATTCCTGATG GAGTGTCGGTCTCTTGCACCGACACTCCATCAGGAAT GGG-3 0 ; S6K1 sense: 5 0 -AATTCCCGGGAGTTGGACCATA TGAACTTGCAAGAGAAGTTCATATGGTCCAACTCCC TTTTTG-3 0 , anti-sense: 5 0 -GATCCAAAAAGGGAGTTGG ACCATATGAACTTCTCTTGCAAGTTCATATGGTCCAA CTCCCGGG-3 0 . Lentiviral shRNA constructs targeting raptor and rictor were gifts from Dr David M Sabatini (Massachusetts Institute of Technology, Cambridge, MA, USA). Lentiviral shRNA constructs were made and used, as described .
Western blot analysis
Western blot was performed as described previously . The primary antibodies used included antibodies to AU1, raptor, rictor (Bethyl Laboratories), HA, phospho-S6K1 (Thr389), S6K1, eIF4E, p-Akt (S473), Akt, mTOR, b-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 4E-BP1 (Zymed Laboratories, South San Francisco, CA, USA), phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein (Cell Signaling, Beverly, MA, USA), phosphotyrosine (p-Tyr), FAK, paxillin and p130
Cas (BD Biosciences, Lexington, KY, USA). To semiquantitate the intensities of the bands NIH ImageJ was used.
Single cell motility assay The single cell motility assay was performed as described .
F-actin staining
Serum-starved cells grown on glass coverslips in 6-well plates were pretreated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml) for B1 h. Cells were then fixed with 4% ice cold paraformaldehyde in phosphate-buffered saline for 20 min at 4 1C and permeabilized with 0.2% Triton X-100 in phosphate-buffered saline for 5 min. Cells were stained with FITC-conjugated phalloidin (1 mg/ml, Sigma, St Louis, MO, USA) for 30 min. Actin filaments (F-actin) were visualized and photographed with a Nikon TE300 digital inverted microscope. Percentage of cells with lamellipodia formation was determined by randomly counting at least 200 cells under the fluorescence microscope using Â 600 magnification.
Detection of phosphorylation of the focal adhesion proteins Serum-starved cells were pretreated with or without rapamycin (100 ng/ml) for 2 h, and then stimulated with IGF-I (10 ng/ml) for 10 min. Cells were lysed in RIPA buffer, as described . Immunoprecipitation was performed by incubation of cell lysates (500 mg) with mouse monoclonal antibody to p-Tyr (5 mg) (BD Pharmingen, San Jose, CA, USA), plus protein A/G-agarose beads (Santa Cruz Biotechnology) overnight at 4 1C, followed by immunoblotting with antibodies to FAK, paxillin and p130 Cas , respectively. IgG-heavy chain and light chain from each immunoprecipitated sample are shown as loading control. In some cases, immunoprecipitation was performed by incubation of cell lysates (500 mg) with antibodies to FAK, paxillin and p130 Cas , respectively, followed by immunoblotting with antibodies to p-Tyr, FAK, paxillin and p130 Cas , respectively.
Statistical analysis
Data were expressed as means ± s.d. and statistically subjected to Student's unpaired t-test. A level of Po0.05 was considered to be significant.
